HAO Siguo, MD, PhD, is currently Chief Hematology Consultant at Jiahui International Hospital. He’s also the Director and Academic Leader of the Department of Hematology at Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine. He also serves as Chief Physician, Professor, Doctoral and Postdoctoral Supervisor.

Dr. HAO earned his Ph.D. in Hematology in 2003 from Shanghai Second Medical University and the Shanghai Institute of Hematology. In 2000, he conducted advanced clinical training in hematopoietic stem cell transplantation (HSCT) as a visiting scholar at the Blood Center of Singapore General Hospital. From 2004 to 2007, he pursued postdoctoral research in tumor immunotherapy in Canada, focusing on translational applications in hematologic malignancies

Dr. HAO has almost 40 years of medical practicing experience. He specializes in the treatment of difficult and complicated hematological diseases, such as acute/chronic leukemia, malignant lymphoma, multiple myeloma, myelodysplastic syndrome (MDS), aplastic anemia, and anemia, thrombocytopenia caused by various reasons.

Dr. HAO has made outstanding achievements in the field of cellular immunotherapy. Since 2017, he has pioneered CAR-T cell therapy for lymphoma and multiple myeloma, accumulating extensive experience in clinical practice, particularly in managing complex and high-risk cases. He demonstrates exceptional therapeutic capabilities in challenging situations including extramedullary lesions, severe comorbidities, elderly patients, or relapsed/refractory cases after multiple lines of therapy, enabling him to develop individualized treatment plans and meticulously manage treatment-related adverse events. To date, numerous patients with complex conditions have achieved deep remission through his CAR-T treatments, with the longest disease-free survival exceeding 8 years, confirming the long-term effectiveness of his therapeutic strategies. He led a groundbreaking clinical study on CAR-T cell therapy for multiple myeloma, achieving remarkable efficacy and safety outcomes. This research was selected for oral presentations at the American Society of Hematology (ASH) Annual Meeting and the International Myeloma Working Group (IMWG) conference on multiple occasions, with the findings published in Haematologica, a top-tier hematology journal. Based on this clinical trial, "Zevor-cel" (also known as CT053) was approved by China's National Medical Products Administration (NMPA, formerly SFDA) in June 2023, becoming a widely accessible cellular therapy for patients.

Additionally, Dr. Hao has profound expertise in hematopoietic stem cell transplantation (HSCT), specializing in both autologous and allogeneic transplants (including haploidentical and umbilical cord blood transplantation). Under his leadership, Xinhua Hospital's Department of Hematology has become one of the few facilities in Shanghai performing cord blood transplants for adult malignant hematologic diseases, successfully treating nearly 100 patients with the longest disease-free survival exceeding 12 years.

Dr. HAO serves as the Vice Chairman of the 10th and 11th Shanghai Hematology Society of Chinese Medical Association, the Vice Chairman of Hematology and Oncology Branch of Shanghai Anti-Cancer Association, the member of Hematology Branch of Chinese Geriatrics Society, the member of Cord Blood Application Committee of Chinese Maternal and Child Health Association, the Vice President of Shanghai Hematopoietic Stem Cell Transplantation Alliance, the Standing Committee member of Hematology Branch of Shanghai Traditional Chinese and Western Medicine Association, the member of Expert Committee of Chinese Stem Cell Bank, the Deputy Director of Shanghai Institute of Hematology, and the member of Hematology Branch of Shanghai Immunology Society. He has undertaken and completed several provincial and ministerial scientific research projects including projects funded by National Natural Science Foundation. Dr. HAO has published more than 100 academic papers, including more than 50 SCI papers. He has presided over 4 National Natural Science Foundation projects. He has also presided several research projects of Shanghai Science and Technology Commission, Health Commission and Shanghai Shenkang Hospital Development Center. Dr. HAO also has been in charge of multiple clinical research projects. He chaired the BCMA CAR-T cell therapy for R/R multiple myeloma program, which has been communicated in several oral presentations at international congresses such as IMWG, ASH, etc., and the results of his research have also been published in the journal Haematologica 2023.

Dr. XU Rong serves as an attending physician in medical oncology department of Jiahui International Cancer Center. Dr. Xu got her Bachelor’s Degree in Clinical Medicine in 2003 and Medical Master’s Degree in Hematology in 2007 from Shanghai Jiaotong University School of Medicine. From 2007 to 2017, Dr. Xu worked in the First People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine. Before joining Jiahui, Dr. Xu was in charge of the HSCT unit in a hematology hospital, specializing in autologous and allogeneic hematopoietic stem cell transplantation and CAR-T cell therapy for relapsed and refractory hematologic tumors. She is adept at managing complications in allogeneic hematopoietic stem cell transplantation, treating post allogeneic HSCT problems such as GVHD, infections, primary and secondary graft failure, thrombotic complications, tumor relapse, etc. Dr. Xu also has extensive experience in autologous hematopoietic stem cell transplantation for multiple myeloma and lymphoma, and CAR-T cell therapy including auto-HSCT bridging CAR-T, tandem CAR-T, double-target CAR-T. Dr. Xu has mastered the technology of invasive and non-invasive mechanical ventilation, continuous renal replacement therapy, hemodynamic monitoring, and intensive rehabilitation techniques. Dr. Xu is qualified in internal medicine, critical care medicine and rehabilitation medicine. As for academic field, she has published more than ten Chinese core journal articles and two SCI papers.

Dr. Dong Yan is currently serving as a medical oncologist at Jiahui International Cancer Center. She graduated with a bachelor’s degree in Clinical Medicine from Peking University Health Science Center in 2002 and received her Ph.D. from the Graduate School of Medicine at the University of Tokyo in 2008. Before joining Jiahui Health, Dr. Dong worked at Tongji Hospital in Shanghai.

Dr. Dong has dedicated her career to clinical and research work in hematology. She is highly proficient in diagnosing and treating a wide range of common blood disorders, including various types of anemia, leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes (MDS), and thrombocytopenia. She has also accumulated clinical experience in advanced blood cancer therapies such as autologous stem cell transplantation, allogeneic hematopoietic stem cell transplantation, and CAR-T.

Dr. Dong has published several papers in both domestic and international core journals and is currently a committee member of the Hematology Branch of Shanghai Medical Association（SMA）.